Cipher Pharmaceuticals Inc. (CPH.TO)
CAD 14.04
(-2.23%)
CAD 14.04
(-2.23%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 17.09 Million USD | 2.46% |
| 2022 | 16.68 Million USD | -8.63% |
| 2021 | 18.25 Million USD | -1.57% |
| 2020 | 18.55 Million USD | -5.09% |
| 2019 | 19.54 Million USD | -4.36% |
| 2018 | 20.43 Million USD | -46.8% |
| 2017 | 38.41 Million USD | 6.26% |
| 2016 | 36.15 Million USD | 13.39% |
| 2015 | 31.88 Million USD | 341.03% |
| 2014 | 7.22 Million USD | -71.35% |
| 2013 | 25.23 Million USD | 261.53% |
| 2012 | 6.98 Million USD | 99.68% |
| 2011 | 3.49 Million USD | -35.08% |
| 2010 | 5.38 Million USD | 77.34% |
| 2009 | 3.03 Million USD | 139.46% |
| 2008 | 1.26 Million USD | 242.12% |
| 2007 | 370.59 Thousand USD | -52.43% |
| 2006 | 778.99 Thousand USD | 20.47% |
| 2005 | 646.63 Thousand USD | -97.46% |
| 2004 | 25.41 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 4.81 Million USD | 21.36% |
| 2024 Q2 | 4.19 Million USD | -12.76% |
| 2023 Q2 | 4.22 Million USD | 8.14% |
| 2023 Q4 | 3.96 Million USD | -20.57% |
| 2023 Q1 | 3.9 Million USD | -1.61% |
| 2023 FY | 17.09 Million USD | 2.46% |
| 2023 Q3 | 4.99 Million USD | 18.1% |
| 2022 Q2 | 4.48 Million USD | 4.52% |
| 2022 Q4 | 3.97 Million USD | 1.04% |
| 2022 FY | 16.68 Million USD | -8.63% |
| 2022 Q1 | 4.29 Million USD | -12.76% |
| 2022 Q3 | 3.93 Million USD | -12.35% |
| 2021 Q4 | 4.92 Million USD | 32.15% |
| 2021 Q1 | 4.52 Million USD | -15.19% |
| 2021 Q2 | 5.08 Million USD | 12.41% |
| 2021 Q3 | 3.72 Million USD | -26.84% |
| 2021 FY | 18.25 Million USD | -1.57% |
| 2020 FY | 18.55 Million USD | -5.09% |
| 2020 Q1 | 5.05 Million USD | -0.88% |
| 2020 Q2 | 3.98 Million USD | -21.08% |
| 2020 Q3 | 4.17 Million USD | 4.77% |
| 2020 Q4 | 5.33 Million USD | 27.83% |
| 2019 Q2 | 4.87 Million USD | 8.42% |
| 2019 Q4 | 5.09 Million USD | 0.47% |
| 2019 Q3 | 5.07 Million USD | 3.98% |
| 2019 FY | 19.54 Million USD | -4.36% |
| 2019 Q1 | 4.49 Million USD | -21.11% |
| 2018 Q2 | 6.39 Million USD | 56.83% |
| 2018 FY | 20.43 Million USD | -46.8% |
| 2018 Q4 | 5.7 Million USD | 33.78% |
| 2018 Q3 | 4.26 Million USD | -33.33% |
| 2018 Q1 | 4.07 Million USD | -64.48% |
| 2017 Q3 | 9.69 Million USD | 1.98% |
| 2017 Q1 | 7.73 Million USD | -13.4% |
| 2017 FY | 38.41 Million USD | 6.26% |
| 2017 Q4 | 11.47 Million USD | 18.4% |
| 2017 Q2 | 9.5 Million USD | 22.89% |
| 2016 Q3 | 8.45 Million USD | -20.49% |
| 2016 FY | 36.15 Million USD | 13.39% |
| 2016 Q2 | 10.63 Million USD | 30.92% |
| 2016 Q1 | 8.12 Million USD | -11.27% |
| 2016 Q4 | 8.93 Million USD | 5.62% |
| 2015 Q3 | 7.61 Million USD | -3.65% |
| 2015 FY | 31.88 Million USD | 341.03% |
| 2015 Q4 | 9.15 Million USD | 20.28% |
| 2015 Q2 | 7.9 Million USD | 11.91% |
| 2015 Q1 | 7.06 Million USD | 11.59% |
| 2014 Q4 | 6.32 Million USD | -0.2% |
| 2014 FY | 7.22 Million USD | -71.35% |
| 2014 Q1 | 7.03 Million USD | -37.39% |
| 2014 Q2 | 8.04 Million USD | 14.36% |
| 2014 Q3 | 6.33 Million USD | -21.23% |
| 2013 Q4 | 11.23 Million USD | 106.16% |
| 2013 Q2 | 5.24 Million USD | 78.83% |
| 2013 Q1 | 2.93 Million USD | 17.78% |
| 2013 FY | 25.23 Million USD | 261.53% |
| 2013 Q3 | 5.45 Million USD | 3.92% |
| 2012 Q4 | 2.49 Million USD | 37.48% |
| 2012 FY | 6.98 Million USD | 99.68% |
| 2012 Q1 | 1.81 Million USD | 70.4% |
| 2012 Q2 | 1.6 Million USD | -11.76% |
| 2012 Q3 | 1.81 Million USD | 13.12% |
| 2011 Q2 | 750.62 Thousand USD | 8.08% |
| 2011 FY | 3.49 Million USD | -35.08% |
| 2011 Q1 | 694.5 Thousand USD | -46.46% |
| 2011 Q4 | 1.06 Million USD | -1.31% |
| 2011 Q3 | 1.07 Million USD | 43.79% |
| 2010 FY | 5.38 Million USD | 77.34% |
| 2010 Q3 | 1.04 Million USD | -50.21% |
| 2010 Q2 | 2.1 Million USD | 133.66% |
| 2010 Q1 | 900.52 Thousand USD | 7.17% |
| 2010 Q4 | 1.29 Million USD | 23.81% |
| 2009 Q4 | 840.28 Thousand USD | -15.82% |
| 2009 FY | 3.03 Million USD | 139.46% |
| 2009 Q1 | 476.75 Thousand USD | 133.47% |
| 2009 Q2 | 584 Thousand USD | 22.5% |
| 2009 Q3 | 998.22 Thousand USD | 70.93% |
| 2008 Q4 | 204.2 Thousand USD | -67.83% |
| 2008 FY | 1.26 Million USD | 242.12% |
| 2008 Q3 | 634.8 Thousand USD | 133.25% |
| 2008 Q2 | 272.15 Thousand USD | 58.27% |
| 2008 Q1 | 171.96 Thousand USD | 1.06% |
| 2007 Q4 | 170.15 Thousand USD | 13.37% |
| 2007 Q3 | 150.08 Thousand USD | 219.52% |
| 2007 FY | 370.59 Thousand USD | -52.43% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | 46.97 Thousand USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 FY | 778.99 Thousand USD | 20.47% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 FY | 646.63 Thousand USD | -97.46% |
| 2005 Q1 | - USD | 0.0% |
| 2004 Q2 | 4.37 Million USD | 81.12% |
| 2004 Q1 | 2.41 Million USD | 0.0% |
| 2004 Q3 | 6.29 Million USD | 43.81% |
| 2004 FY | 25.41 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Aurora Cannabis Inc. | 131.46 Million CAD | 86.998% |
| Avicanna Inc. | 6.65 Million CAD | -156.702% |
| Avant Brands Inc. | 12.43 Million CAD | -37.492% |
| Cardiol Therapeutics Inc. | -248.35 Thousand CAD | 6982.487% |
| Crescita Therapeutics Inc. | 10.36 Million CAD | -64.927% |
| Knight Therapeutics Inc. | 152.65 Million CAD | 88.803% |
| MediPharm Labs Corp. | 5.85 Million CAD | -191.939% |
| OrganiGram Holdings Inc. | 35.07 Million CAD | 51.265% |
| Canopy Growth Corporation | 80.88 Million CAD | 78.867% |
| Willow Biosciences Inc. | -659 Thousand CAD | 2693.778% |
| Auxly Cannabis Group Inc. | 21.27 Million CAD | 19.664% |